AR Snavely, K Heo,
V Petrova, TSY Ho… - Disease Models & …, 2022 - ncbi.nlm.nih.gov
The proteosome inhibitor bortezomib has revolutionized the treatment of multiple
hematologic malignancies, but in many cases, its efficacy is limited by a dose-dependent …